Sacituzumab Govitecan

Results presented from TROPiCS-02 showed that sacituzumab govitecan was effective in a subset of patients with breast cancer regardless of Trop-2 expression level, according to data presented at San Antonio Breast Cancer Symposium.

In this video, Erica L. Mayer, MD, MPH, discusses important takeaways from breast cancer sessions at this year’s European Society for Medical Oncology Congress.

The FDA granted priority review to sacituzumab govitecan-hziy for treatment of certain patients with advanced breast cancer.

Healio rounded up the top breast cancer coverage presented and discussed at ASCO Annual Meeting in Chicago.

CHICAGO — Sacituzumab govitecan significantly extended PFS vs. single-agent chemotherapy among patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer, according to study results.

A phase 3 study of sacituzumab govitecan-hziy met its primary endpoint of PFS among a subset of patients with hormone receptor-positive, HER2-negative metastatic breast cancer, according to topline data released by the agent’s manufacturer.

The FDA today granted accelerated approval to sacituzumab govitecan for the treatment of patients with locally advanced or metastatic urothelial cancer who previously received platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor.

The FDA granted regular approval to sacituzumab govitecan for treatment of certain patients with triple-negative breast cancer.

Women with metastatic triple-negative breast cancer benefited from sacituzumab govitecan irrespective of their Trop-2 expression level and BRCA1/BRCA2 mutation status, according to data from the phase 3 ASCENT study.

This year has seen some groundbreaking advances in genitourinary oncology, particularly in the fields of prostate, kidney and urothelial cancers.